| 1 |
Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China,1990-2010: findings from the Global Burden of Disease Study 2010[J]. Lancet, 2013,381(9882):1987-2015.
|
| 2 |
Omata M, Lesmana LA, Tateishi R, et al. Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma [J]. HepatolInt, 2010, 4(2):439-474.
|
| 3 |
European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012,56(4):908-943.
|
| 4 |
Sturgeon CM, Duffy MJ, Hofmann BR, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers[J].Clin Chem, 2010,56(6):e1-e48.
|
| 5 |
Murphy JE, Ryan DP. American Society of Clinical Oncology 2010 colorectal update[J]. Expert Rev Anticancer Ther, 2010,10(9):1371-1373.
|
| 6 |
Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer[J]. N Engl J Med, 2013,369(12):1106-1114.
|
| 7 |
Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis[J].Ann Intern Med, 2014,160(3):171.
|
| 8 |
Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med,2014,370(14):1287-1297.
|
| 9 |
Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening[J]. CA Cancer J Clin, 2014,64(1):30-51.
|
| 10 |
Dinis-Ribeiro M, Yamaki G, Miki K, et al.Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening[J]. J Med Screen, 2004,11(3):141-147.
|
| 11 |
Hayes JH, Barry MJ. Screening for prostate cancer with the prostatespecific antigen test: a review of current evidence[J]. JAMA,2014,311(11):1143-1149.
|
| 12 |
Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial[J]. N Engl J Med,2009,360(13):1310-1319.
|
| 13 |
Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up[J]. N Engl J Med, 2012,366(11): 981-990.
|
| 14 |
Steenbergen RD, Snijders PJ, Heideman DA, et al. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions[J]. Nat Rev Cancer, 2014,14(6):395-405.
|
| 15 |
Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian(PLCO) Cancer Screening Randomized Controlled Trial[J]. JAMA,2011,305(22):2295-2303.
|
| 16 |
Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study[J]. J Natl Cancer Inst, 2010,102(1):26-38.
|
| 17 |
Escudero JM, Auge JM, Filella X, et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases[J]. ClinChem,2011,57(11):1534-1544.
|
| 18 |
Bauça JM, Martínez-Morillo E, Diamandis EP. Peptidomics of urine and other biofluids for cancer diagnostics[J]. ClinChem,2014,60(8):1052-1061.
|
| 19 |
Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy:monitoring cancer-genetics in the blood[J]. Nat Rev ClinOncol,2013,10(8):472-484.
|
| 20 |
Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer[J]. Nat Rev Clin Oncol,2014,11(3):145-156.
|
| 21 |
Moyer VA, US Preventive Services Task Force. Risk assessment,genetic counseling, and genetic testing for BRCA-related cancer in women: US Preventive Services Task Force recommendation statement[J]. Ann Intern Med, 2014,160(4):271-281.
|
| 22 |
Pavlou MP, Diamandis EP, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic[J]. Clin Chem,2013,59(1):147-157.
|
| 23 |
Morgan SR, Whiteley J, Donald E, et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples[J]. Clin Med Insights Pathol, 2012,5:15-22.
|
| 24 |
Chrystoja CC, Diamandis EP. Whole genome sequencing as a diagnostic test: challenges and opportunities[J]. ClinChem,2014,60(5):724-733.
|